Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops drugs for neurological and oncological diseases in Taiwan and the rest of Asia. The company offers Naldebain (LT-1001), an analgesic injection for postoperative pain. It also develops LT3001, which has completed Phase 2b clinical trials for the treatment of acute ischemic stroke; LT6001, which is in pre-clinical trials for the treatment of neurological disorders; and CS028, which is in the pre-clinical stage for the treatment of solid tumors. In addition, the company engages in the investment, new drug development consulting, and service and transfer of techniques activities. The company was formerly known as SunTen Phytotech Co., Ltd. and changed its name to Lumosa Therapeutics Co., Ltd. in June 2014. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.
Frequently asked questions
What sector does Lumosa Therapeutics Co. Ltd. (6535) operate in?
Lumosa Therapeutics Co. Ltd. belongs to the Other sector and operates in the Biotechnology industry.
What is Lumosa Therapeutics Co. Ltd. (6535) current stock price?
As of the latest data, Lumosa Therapeutics Co. Ltd. stock price is NT$86.10, with a previous close of NT$87.90. Lumosa Therapeutics Co. Ltd. lost -NT$1.80 in the last trading session, representing a -2.05% loss.
What is Lumosa Therapeutics Co. Ltd. (6535) current market capitalization?
Lumosa Therapeutics Co. Ltd. market cap is approximately 14.42 billion.
What is Lumosa Therapeutics Co. Ltd. (6535) Earnings Per Share (EPS)?
The trailing EPS is -NT$2.14, and the forward EPS is -NT$2.52.
Does Lumosa Therapeutics Co. Ltd. (6535) pay dividends?
No. Lumosa Therapeutics Co. Ltd. does not pay a dividend.
How did Lumosa Therapeutics Co. Ltd. (6535) perform in its most recent earnings report?
In the last report (March 31, 2026), Lumosa Therapeutics Co. Ltd. posted an EPS surprise of 100% and a revenue surprise of -35.96%.
What is Lumosa Therapeutics Co. Ltd. (6535) beta (volatility) score?
Lumosa Therapeutics Co. Ltd. has a beta of 0.119, indicating lower volatility than the overall market.
